Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies (Hélico-MQ)

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies: Helico-MQ Interventional Study

Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.

Study Overview

• Status: Recruiting
• Conditions: Stomach Neoplasms; Gastric Neoplasms; Helicobacter Pylori
• Intervention / Treatment: Biological: Helicobacter Pylori detection

Detailed Description

In the Antilles-Guyana, gastric cancer affects approximately 80 men and women each year in Guadeloupe and Martinique, and 20 in French Guiana. It is more frequent than in France and represents 4.5% of cancers in men in Martinique, 5.3% in Guadeloupe and 5.7% in French Guyana. It is the 3rd most common cancer site in men in Guadeloupe and Martinique, and the 4th in French Guiana. In women, it is the 3rd most frequent cancer in Martinique and the 4th in Guadeloupe, whereas it is less frequent in French Guiana.

Studies are needed to estimate this prevalence in the general population and in cancer patients. The prevalence of Helicobacter pylori infection is not well known in the general population in the Caribbean and when gastric cancer is diagnosed, the bacterium is rarely tested.

Dietary habits in our regions are characterized by a high consumption of salt (salted), meat and smoked fish. These dietary habits, common to some Southeast Asian countries, could partly explain the high incidence of stomach cancer observed. But environmental risk factors could also be involved.

Patients referred to gastroenterology with a suspected endoscopic diagnosis of gastric cancer will be offered to participate in the study after the fibroscopy has been performed and their consent will be obtained for the use of diagnostic specimen remains for research purposes.

• Study Type: Observational
• Enrollment (Estimated): 112

Contacts and Locations

• Study Contact: Name: Clarisse JOACHIM-CONTARET; Phone Number: +596596559674; Email: clarisse.joachim@chu-martinique.fr
• Study Contact Backup: Name: Mickaelle ROSE; Phone Number: +596596592623; Email: mickaelle.rose@chu-martinique.fr

Study Locations

• Martinique
  • Fort-de-France, Martinique, 97261
    • Recruiting
    • CHU Martinique
    • Principal Investigator: Thierry BORTUZZO
    • Contact: Mickaelle ROSE; Phone Number: +596596592623; Email: mickaelle.rose@chu-martinique.fr
    • Principal Investigator: Amélie BIRON

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Eligible patients (with a suspected endoscopic diagnosis of gastric cancer) will be selected either at the Martinique University Hospital or at the Sainte-Marie clinic during consultations or hospitalizations.

Description

Inclusion Criteria:

1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer
2. Patient having read the information note and having signed the consent to participate in the study
3. Patient with social security coverage

Exclusion Criteria:

1. Refusal to participate
2. Patient who could not answer the questionnaires
3. Patient not affiliated to a social security system
4. Patient not fluent in French
5. Patient under legal protection (legal protection, guardianship, curators, etc.)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Helicobacter Pylori detection; Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).	Biological: Helicobacter Pylori detection; Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup. Additional data will be collected through a questionnaire.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Estimation of the prevalence of Helicobacter pylori	Helicobacter Pylori has detected by immunohistochemistry in the stomach of patients with gastric cancer.	At baseline

Collaborators and Investigators

• Sponsor: University Hospital Center of Martinique
• Investigators: Principal Investigator: Clarisse JOACHIM-CONTARET, CHU Martinique

Study record dates

Study Major Dates

• Study Start (Actual): October 9, 2025
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: June 16, 2021
• First Submitted That Met QC Criteria: June 30, 2021
• First Posted (Actual): July 2, 2021

Study Record Updates

• Last Update Posted (Actual): March 31, 2026
• Last Update Submitted That Met QC Criteria: March 26, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Prevalence; Gastric cancer; Helicobacter Pylori; French West-Indies
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms
• Other Study ID Numbers: 20_RIPH2_22; 2020-A02412-37 (Other Identifier: DGS, Ministry of Health)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No